IDEXX Laboratories (NASDAQ:IDXX) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective on the stock in a research report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research report on Friday, October 6th. Bank of America raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research report on Wednesday, August 23rd. Finally, Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $173.67.

Shares of IDEXX Laboratories (NASDAQ IDXX) opened at $156.60 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a 12-month low of $113.92 and a 12-month high of $173.01. The company has a market capitalization of $13,658.50, a price-to-earnings ratio of 52.73, a P/E/G ratio of 2.37 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same period last year, the firm posted $0.62 earnings per share. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. research analysts predict that IDEXX Laboratories will post 3.24 EPS for the current fiscal year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the transaction, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last three months, insiders sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. WMS Partners LLC lifted its holdings in IDEXX Laboratories by 0.3% in the second quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock valued at $256,000 after acquiring an additional 4 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in IDEXX Laboratories by 0.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock valued at $1,057,000 after acquiring an additional 19 shares during the period. National Asset Management Inc. lifted its holdings in IDEXX Laboratories by 2.1% in the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock valued at $332,000 after acquiring an additional 42 shares during the period. Advisor Group Inc. lifted its holdings in IDEXX Laboratories by 1.1% in the second quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock valued at $732,000 after acquiring an additional 52 shares during the period. Finally, QS Investors LLC lifted its holdings in IDEXX Laboratories by 1.5% in the second quarter. QS Investors LLC now owns 4,068 shares of the company’s stock valued at $657,000 after acquiring an additional 60 shares during the period. 86.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/18/idexx-laboratories-idxx-stock-rating-lowered-by-bidaskclub.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related stocks with our FREE daily email newsletter.